Anteris Technologies Global Corp. (AVR)
NASDAQ: AVR · Real-Time Price · USD
4.040
-0.020 (-0.49%)
At close: Jun 20, 2025, 4:00 PM
4.070
+0.030 (0.74%)
After-hours: Jun 20, 2025, 5:27 PM EDT
AVR Revenue
Anteris Technologies Global had revenue of $556.00K in the quarter ending March 31, 2025, with 2.14% growth. This brings the company's revenue in the last twelve months to $2.49M, down -8.85% year-over-year. In the year 2024, Anteris Technologies Global had annual revenue of $2.70M, down -1.17%.
Revenue (ttm)
$2.49M
Revenue Growth
-8.85%
P/S Ratio
56.37
Revenue / Employee
$18,331
Employees
136
Market Cap
140.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
| Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
| Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
| Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
| Dec 31, 2020 | 5.46M | -6.54M | -54.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
AVR News
- 11 days ago - Anteris Appoints David Roberts and Gregory Moss to its Board of Directors - GlobeNewsWire
- 2 months ago - Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewsWire
- 3 months ago - Anteris Reports One-Year Patient Outcomes for DurAVR® THV - GlobeNewsWire
- 3 months ago - Anteris Reports 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering - Business Wire
- 6 months ago - Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering - Business Wire
- 6 months ago - Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering - Business Wire
- 7 months ago - Cardiac device maker Anteris Technologies files for $75M IPO - Seeking Alpha